Two compounds, one proposed mechanism — selectively clearing senescent cells. Here is what current human trial data actually shows for each, and where the evidence genuinely diverges.
Senescent cells don't die — they linger, secrete inflammatory signals, and drag down the tissue around them.
Cellular senescence is one of the twelve hallmarks of aging. Senescent cells exit the cell cycle permanently following stress or damage, then accumulate with age and secrete a pro-inflammatory cocktail — the senescence-associated secretory phenotype, or SASP — that drives chronic tissue dysfunction. In mouse models, selectively eliminating these cells extends healthspan. Two pharmacological approaches dominate current human research: the combination of dasatinib and quercetin (D+Q), and the flavonoid fisetin used on its own. Both are proposed senolytics. Their evidence bases are not equivalent.
| Dasatinib + Quercetin | Fisetin | |
|---|---|---|
| FDA-approved use | Dasatinib: certain leukemias (not senolytic use) | None — sold as a dietary supplement |
| Human trial stage | Phase II (Kirkland 2023) | Ongoing — Mayo Clinic trials |
| Pooled hard-outcome HR | None established | None established |
| Geroevidence tier | Emerging | Under editorial review |
| Notable safety consideration | Dasatinib carries myelosuppression risk at its approved oncology dose, higher than senolytic protocols studied | Generally favorable as a dietary flavonoid; limited long-term human safety data |
Dasatinib, a tyrosine kinase inhibitor approved for certain leukemias, combined with quercetin, a flavonoid, was among the first senolytic combinations tested in humans. Early-phase trials, including Kirkland and colleagues' 2023 Phase II work, have evaluated D+Q in small cohorts, generally reporting tolerability at intermittent low doses far below dasatinib's oncology dosing. No pooled hazard ratio for a hard clinical outcome currently exists — published data to date centers on biomarker and feasibility endpoints rather than mortality or major morbidity outcomes.
Fisetin, a flavonoid found in strawberries and other plants, is studied as a senolytic through a proposed mechanism distinct from D+Q's kinase-inhibition pathway. Mayo Clinic-affiliated trials are tracking its effects, but published human evidence specific to longevity or senescence-clearance outcomes has not yet met the threshold Geroevidence requires for a formal evidence tier — at least one published human trial or strong Interventions Testing Program-style lifespan data. Until that threshold is met, fisetin's profile remains marked under editorial review rather than assigned a tier.
D+Q currently has a more developed human trial record than fisetin, but neither compound has produced pooled hazard-ratio data for a hard clinical outcome. Both remain early-stage relative to interventions like GLP-1 agonists or SGLT2 inhibitors, which already have Phase III outcome trials behind them. The senolytic hypothesis itself — that clearing senescent cells improves healthspan — is mechanistically well supported in animal models; translating that into a clinically validated human intervention is the open question for both approaches.
Geroevidence will update both profiles as new trial data, including results from the ongoing Mayo Clinic fisetin work, is published and reviewed.